Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
Author:
Funder
AstraZeneca
Boehringer Ingelheim
Eli Lilly & Co.
GlaxoSmithKline
Menarini/Berlin-Chemie
Merck
Sharp & Dohme
Novartis
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference79 articles.
1. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome;Pfeffer;N. Engl. J. Med.,2015
2. Liraglutide and cardiovascular outcomes in Type 2 diabetes;Marso;N. Engl. J. Med.,2016
3. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes;Marso;N. Engl. J. Med.,2016
4. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes;Holman;N. Engl. J. Med.,2017
5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management;Endocrinology and Metabolism;2024-04-30
2. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-08-30
3. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study;Cardiovascular Diabetology;2023-06-28
4. Primary Occurrence of Cardiovascular Events After Adding Sodium–Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes;Annals of Internal Medicine;2023-06
5. Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami;Inflammopharmacology;2023-04-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3